Market closedNon-fractional

Harmony Biosciences/HRMY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Harmony Biosciences

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Ticker

HRMY

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Plymouth Meeting, United States

Employees

246

HRMY Metrics

BasicAdvanced
$1.9B
Market cap
14.16
P/E ratio
$2.32
EPS
0.72
Beta
-
Dividend rate
$1.9B
0.72
3.109
2.931
34.201
37.46
9.03%
16.30%
28.73%
14.163
3.121
3.6
4.83
9.282
30.92%
-25.15%
45.72%
128.43%

What the Analysts think about HRMY

Analyst Ratings

Majority rating from 7 analysts.
Buy

HRMY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
24.77% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$155M
-8.19%
Net income
$38M
43.98%
Profit margin
24.77%
56.87%

HRMY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.87%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.56
$0.63
$0.45
$0.67
-
Expected
$0.63
$0.65
$0.48
$0.60
$0.01
Surprise
-11.46%
-3.08%
-6.01%
10.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Harmony Biosciences stock?

Harmony Biosciences (HRMY) has a market cap of $1.9B as of July 25, 2024.

What is the P/E ratio for Harmony Biosciences stock?

The price to earnings (P/E) ratio for Harmony Biosciences (HRMY) stock is 14.16 as of July 25, 2024.

Does Harmony Biosciences stock pay dividends?

No, Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders as of July 25, 2024.

When is the next Harmony Biosciences dividend payment date?

Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders.

What is the beta indicator for Harmony Biosciences?

Harmony Biosciences (HRMY) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Harmony Biosciences stock

Buy or sell Harmony Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing